By Ayaz Majid, PhD
This article explores emerging strategies for cost-effective universal screening of congenital cytomegalovirus (cCMV), a leading non-genetic cause of childhood hearing loss and neurodevelopmental disability. Readers will review early-life detection within the critical 21-day window, recommended specimen types—including saliva, urine, and dried blood spots—and the strengths and limitations of each. The article highlights the clinical advantages of PCR-based molecular testing and examines how sample pooling can expand access while reducing costs. Legislative momentum and evolving laboratory workflows are also discussed, underscoring practical pathways to broader, high-confidence newborn cCMV screening and earlier intervention.
LEARNING OBJECTIVES
Upon completion of this article, the reader will be able to:
- Discuss cCMV sequale and how to detect the virus in the early stages of life.
- List the various sample types for for cCMV identification and specimen of choice for screening and confirmatory testing.
- Describe the benefits of using PCR testing and sample pooling in the detection of cCMV.
- List testing methods to identify cCMV and discuss the limitations of each.

Ayaz Majid, PhD is Director, Product Management at Diasorin. With extensive expertise in molecular diagnostics, he is passionate about advancing meaningful solutions that improve patient healthcare.

